Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31418373 | 0.86 | ADRA1D (0.52) | KDM4EPDPK1MAPK10ALDH1A1USP2 | |
| SCHEMBL3348293 | 0.83 | KDM4E (0.67) | KMT2AKDM4EMAPK10ALDH1A1USP2 | |
| SCHEMBL15241737 | 0.83 | BRD4 (0.54) | KDM4EMAPK10ALDH1A1LMNAPOLB | |
| SCHEMBL12120841 | 0.82 | KDM4E (0.53) | KMT2AKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL19787905 | 0.80 | PDPK1 (0.42) | KDM4EPDPK1MAPK10ALDH1A1USP2 | |
| SCHEMBL13307005 | 0.77 | POLB (0.41) | KDM4EPDPK1MAPK10ALDH1A1USP2 | |
| SCHEMBL3350219 | 0.77 | ADRA1D (0.58) | KMT2AKDM4EPDPK1MAPK10ALDH1A1 | |
| SCHEMBL13362335 | 0.76 | KMT2A (0.52) | KMT2AMAPK10ALDH1A1USP2LMNA | |
| SCHEMBL5183997 | 0.76 | MAPK10 (0.52) | KDM4EPDPK1MAPK10ALDH1A1USP2 | |
| SCHEMBL4387866 | 0.76 | KDM4E (0.53) | KMT2AKDM4EPDPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| CN-101541783-A | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KMT2A 1050/4885KDM4E 629/4885PDPK1 6/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | KMT2A 1202/4885KDM4E 599/4885PDPK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.